De-Nol, 120 mg 112 pcs.

An anti-ulcer drug with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent action.

In the acidic environment of the stomach insoluble bismuth oxychloride and citrate are precipitated and chelated compounds with protein substrate are formed in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of prostaglandin E, mucus formation and hydrocarbonate secretion, stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to pepsin, hydrochloric acid, enzymes and bile acid salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.

Pharmacokinetics

absorption and distribution

Bismuth tricalium dicitrate is practically not absorbed from the GI tract.

Evacuation< /em>

Evacuated mainly with the feces. Minor amounts of bismuth entered into the plasma are excreted by the kidneys.

Indications

chronic gastritis and gastroduodenitis in the acute phase, incl. associated with Helicobacter pylori;
peptic ulcer of the stomach and duodenum in the acute phase, incl. associated with Helicobacter pylori;
irritable bowel syndrome, which occurs predominantly with symptoms of diarrhea;
functional dyspepsia not associated with organic gastrointestinal diseases.

Pharmacological effect

Antiulcer drug with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effects.

In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are deposited, and chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of prostaglandin E, mucus formation and bicarbonate secretion, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.

Pharmacokinetics

Suction and distribution

Bismuth tripotassium dicitrate is practically not absorbed from the gastrointestinal tract.

Removal

It is excreted mainly in feces. A small amount of bismuth entering the plasma is excreted by the kidneys.

Special instructions

The drug should not be used for more than 8 weeks. It is also not recommended to exceed the established daily doses for adults and children during treatment. During treatment with De-Nol®, you should not use other drugs containing bismuth. At the end of a course of treatment with the drug in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3–58 mcg/l, and intoxication is observed only at concentrations above 100 mcg/l.

When using De-Nol®, stool may turn dark due to the formation of bismuth sulfide. Sometimes there is a slight darkening of the tongue.

Active ingredient

Bismuth tripotassium dicitrate

Composition

Active ingredient:

bismuth tripotassium dicitrate 304.6 mg;

Excipients:

corn starch – 70.6 mg,

povidone K30 – 17.7 mg,

potassium polyacrylate – 23.6 mg,

macrogol 6000 – 6 mg,

magnesium stearate – 2 mg

Contraindications

Hypersensitivity;

severe renal dysfunction.

Side Effects

From the digestive system: nausea, vomiting, more frequent bowel movements, and constipation may occur. These phenomena are not dangerous to health and are temporary.

Allergic reactions: skin rash, skin itching.

Interaction

For half an hour before and after taking De-Nol®, it is not recommended to take other drugs internally, as well as take food and liquids, in particular antacids, milk, fruits and fruit juices. This is due to the fact that when taken orally simultaneously, they can affect the effectiveness of De-Nol®.

Overdose

Symptoms (with long-term use of doses exceeding the recommended): impaired renal function. These symptoms are completely reversible when De-Nol® is discontinued.

Treatment: gastric lavage, administration of activated charcoal and saline laxatives. Further treatment should be symptomatic. In case of impaired renal function, accompanied by a high level of bismuth in the blood plasma, the use of complexing agents – dimercaptosuccinic and dimercaptopropanesulfonic acids. In case of severe renal dysfunction, hemodialysis is indicated.

Storage conditions

At a temperature not exceeding 25 °C.

Shelf life

4 years

Manufacturer

ZiO-Zdorovye CJSC, Russia